Biologic agent activity in chronic lymphocytic leukemia: A framework for future therapies

Chadi Nabhan, Neil Dalal, Jayesh Mehta, Neil Elliot Kay

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The previous decade has witnessed remarkable advances in our understanding and treatment of chronic lymphocytic leukemia. Chemoimmunotherapy has provided patients with unprecedented remission rates and has improved survival compared to chemotherapy alone. However, the availability of targeted therapies and monoclonal antibodies argues for exploring non-cytotoxic and biologic regimens for this disease. In this article, we review available targeted and non-chemotherapeutic agents for CLL, attempting to position these therapies in the treatment paradigm of CLL in the era of risk stratification as we move forward.

Original languageEnglish (US)
Pages (from-to)374-386
Number of pages13
JournalLeukemia and Lymphoma
Volume52
Issue number3
DOIs
StatePublished - Mar 2011

Fingerprint

Biological Factors
B-Cell Chronic Lymphocytic Leukemia
Therapeutics
Monoclonal Antibodies
Drug Therapy
Survival

Keywords

  • chemotherapeutic approaches
  • Immunotherapeutic approaches
  • lymphoid leukemia
  • pharmacotherapeutics
  • signaling therapies

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Biologic agent activity in chronic lymphocytic leukemia : A framework for future therapies. / Nabhan, Chadi; Dalal, Neil; Mehta, Jayesh; Kay, Neil Elliot.

In: Leukemia and Lymphoma, Vol. 52, No. 3, 03.2011, p. 374-386.

Research output: Contribution to journalArticle

Nabhan, Chadi ; Dalal, Neil ; Mehta, Jayesh ; Kay, Neil Elliot. / Biologic agent activity in chronic lymphocytic leukemia : A framework for future therapies. In: Leukemia and Lymphoma. 2011 ; Vol. 52, No. 3. pp. 374-386.
@article{72f98dbd748c49e4ba84c3eb6120bdec,
title = "Biologic agent activity in chronic lymphocytic leukemia: A framework for future therapies",
abstract = "The previous decade has witnessed remarkable advances in our understanding and treatment of chronic lymphocytic leukemia. Chemoimmunotherapy has provided patients with unprecedented remission rates and has improved survival compared to chemotherapy alone. However, the availability of targeted therapies and monoclonal antibodies argues for exploring non-cytotoxic and biologic regimens for this disease. In this article, we review available targeted and non-chemotherapeutic agents for CLL, attempting to position these therapies in the treatment paradigm of CLL in the era of risk stratification as we move forward.",
keywords = "chemotherapeutic approaches, Immunotherapeutic approaches, lymphoid leukemia, pharmacotherapeutics, signaling therapies",
author = "Chadi Nabhan and Neil Dalal and Jayesh Mehta and Kay, {Neil Elliot}",
year = "2011",
month = "3",
doi = "10.3109/10428194.2010.545461",
language = "English (US)",
volume = "52",
pages = "374--386",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Biologic agent activity in chronic lymphocytic leukemia

T2 - A framework for future therapies

AU - Nabhan, Chadi

AU - Dalal, Neil

AU - Mehta, Jayesh

AU - Kay, Neil Elliot

PY - 2011/3

Y1 - 2011/3

N2 - The previous decade has witnessed remarkable advances in our understanding and treatment of chronic lymphocytic leukemia. Chemoimmunotherapy has provided patients with unprecedented remission rates and has improved survival compared to chemotherapy alone. However, the availability of targeted therapies and monoclonal antibodies argues for exploring non-cytotoxic and biologic regimens for this disease. In this article, we review available targeted and non-chemotherapeutic agents for CLL, attempting to position these therapies in the treatment paradigm of CLL in the era of risk stratification as we move forward.

AB - The previous decade has witnessed remarkable advances in our understanding and treatment of chronic lymphocytic leukemia. Chemoimmunotherapy has provided patients with unprecedented remission rates and has improved survival compared to chemotherapy alone. However, the availability of targeted therapies and monoclonal antibodies argues for exploring non-cytotoxic and biologic regimens for this disease. In this article, we review available targeted and non-chemotherapeutic agents for CLL, attempting to position these therapies in the treatment paradigm of CLL in the era of risk stratification as we move forward.

KW - chemotherapeutic approaches

KW - Immunotherapeutic approaches

KW - lymphoid leukemia

KW - pharmacotherapeutics

KW - signaling therapies

UR - http://www.scopus.com/inward/record.url?scp=79951705088&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951705088&partnerID=8YFLogxK

U2 - 10.3109/10428194.2010.545461

DO - 10.3109/10428194.2010.545461

M3 - Article

C2 - 21323519

AN - SCOPUS:79951705088

VL - 52

SP - 374

EP - 386

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 3

ER -